Pulsed-Field vs Thermal Catheter Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy
JACC: Clinical Electrophysiology · 2025-06 · 11 (6) · 1205-1215
DOI: 10.1016/j.jacep.2025.01.009 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JACC: Clinical Electrophysiology, 2025-06. Verfasst von Samy Gribissa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Département de Cardiologie, Sorbonne Université, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Paris, France. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cardiomyopathy, Hypertrophic, Catheter Ablation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Pulsed-field ablation (PFA) may be beneficial for the treatment of atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy (HCM). OBJECTIVES: The goal of this study was to compare the safety and efficacy of PFA and thermal ablation in patients with HCM and AF. METHODS: From 2016 to 2024, patients with HCM undergoing a first AF ablation using PFA or thermal ablation (cryoballoon or radiofrequency) were retrospectively included from 3 French and Swiss centers. Freedom from atrial arrhythmia (AA) recurrence at the 12-month follow-up was assessed. RESULTS: Overall, 109 patients (median age 60 years; 68% male; 43% paroxysmal AF) with HCM underwent PFA (n = 58) or thermal ablation (n = 51) of AF. In addition to pulmonary vein (PV) isolation, extra-PV ablation was performed in 62% of PFA cases and in 18% of thermal cases. PFA was associated with shorter median procedure times than thermal ablation (81 minutes [Q1-Q3: 60-110 minutes] vs 132 minutes [Q1-Q3: 75-190 minutes]; P < 0.0001) and with less postprocedural heart failure (n = 0 vs n = 4; P = 0.03). Freedom from AA recurrence was 57% (95% CI: 46%-67%) after 12 months. PFA was associated with less AA recurrence than thermal ablation (adjusted HR: 0.46; 95% CI: 0.23-0.91; P = 0.03). Extra-PV ablation was associated with more sustained AA recurrence with thermal ablation (HR: 3.07; 95% CI: 1.21-7.82; P = 0.02) but not with PFA (HR: 1.07; 95% CI: 0.35-3.27; P = 0.91). CONCLUSIONS: In patients with HCM and AF, PFA seems to be associated with better safety and efficacy outcomes than thermal ablation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Département de Cardiologie, Sorbonne Université, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Paris, France.
- Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Department of Cardiology, University Hospital Basel, Basel, Switzerland.
- Département de Cardiologie, Sorbonne Université, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Paris, France; Département de Génétique, Centre de Références des Maladies Cardiaques Héréditaires ou rares, Sorbonne Univ…
- Département de Cardiologie, Sorbonne Université, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Paris, France. Electronic address: mikael.laredo@aphp.fr.
Zitieren
APA
Gribissa, S., Kueffer, T., Knecht, S., Waintraub, X., Badenco, N., Charron, P., Pinon, P., King, R., Gandjbakhch, E., Duthoit, G., Sticherling, C., Reichlin, T., & Laredo, M. (2025). Pulsed-Field vs Thermal Catheter Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. JACC: Clinical Electrophysiology, 11(6), 1205-1215. https://doi.org/10.1016/j.jacep.2025.01.009
Vancouver
Gribissa S, Kueffer T, Knecht S, Waintraub X, Badenco N, Charron P, et al. Pulsed-Field vs Thermal Catheter Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. JACC: Clinical Electrophysiology. 2025;11(6):1205-1215. doi:10.1016/j.jacep.2025.01.009
BibTeX
@article{Gribissa2025,
author = {Gribissa, Samy and Kueffer, Thomas and Knecht, Sven and Waintraub, Xavier and Badenco, Nicolas and Charron, Philippe and Pinon, Pauline and King, Raphael and Gandjbakhch, Estelle and Duthoit, Guillaume and Sticherling, Christian and Reichlin, Tobias and Laredo, Mikael},
title = {Pulsed-Field vs Thermal Catheter Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy},
journal = {JACC: Clinical Electrophysiology},
year = {2025},
volume = {11},
number = {6},
pages = {1205--1215},
doi = {10.1016/j.jacep.2025.01.009}
}
EUVIMED